Publicaciones en colaboración con investigadores/as de GlaxoSmithKline (Spain) (47)

2024

  1. Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care

    BMC Rheumatology, Vol. 8, Núm. 1

2021

  1. Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study (Drugs, (2021), 81, 15, (1763-1774), 10.1007/s40265-021-01597-9)

    Drugs

  2. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study

    Drugs, Vol. 81, Núm. 15, pp. 1763-1774

2020

  1. Management of adult patients with PAH in Spain: current practice, resources, and needs (AIRE17 Study)

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 147-154

2016

  1. The value of biological therapies in the treatment of rheumatic chronic diseases. A systematic review of its pharmacoeconomic evidence in Spain

    Pharmacoeconomics - Spanish Research Articles, Vol. 13, Núm. 2, pp. 69-89

2015

  1. Validation of a Spanish version of the childhood asthma control test (Sc-ACT) for use in Spain

    Anales de Pediatria, Vol. 83, Núm. 2, pp. 94-103

2013

  1. Flow cytometry analysis with a new FITC-conjugated monoclonal antibody-3E12 for HLA-B*57:01 rapid screening in prevention of abacavir hypersensitivity in HIV-1-infected patients

    HIV Clinical Trials, Vol. 14, Núm. 4, pp. 160-164

  2. Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain

    Expert Opinion on Drug Safety, Vol. 12, Núm. 4, pp. 455-463

2011

  1. Ethics on genetic research (1). Pharmacogenetic studies

    Medicina Clinica, Vol. 136, Núm. 15, pp. 678-682

  2. Problemas éticos por el uso de placebo en los ensayos clínicos con fármacos para la migraña. Análisis mediante el método de deliberación moral

    Neurologia, Vol. 26, Núm. 2, pp. 92-99

2010

  1. Antimicrobial resistance among respiratory pathogens in Spain: Latest data and changes over 11 years (1996-1997 to 2006-2007)

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 7, pp. 2953-2959

2009

  1. Prevalence of HLA-B*5701 in HIV-infected patients in spain (results of the epi study)

    HIV Clinical Trials, Vol. 10, Núm. 1, pp. 48-51

2008

  1. Cidal activity of oral third-generation cephalosporins against Streptococcus pneumoniae in relation to cefotaxime intrinsic activity

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 27, Núm. 8, pp. 679-683

  2. Immunogenicity and reactogenicity of a booster dose of a novel combined haemophilus influenzae type b-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age

    Pediatric Infectious Disease Journal, Vol. 27, Núm. 7, pp. 579-588

  3. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

  4. When should re-consent of subjects participating in a clinical trial be requested? A case-oriented algorithm to assist in the decision-making process

    Clinical Pharmacology and Therapeutics, Vol. 83, Núm. 5, pp. 788-793

  5. β-lactam activity against penicillin-resistant Streptococcus pneumoniae strains exhibiting higher amoxicillin versus penicillin minimum inhibitory concentration values: An in vitro pharmacodynamic simulation

    Chemotherapy, Vol. 54, Núm. 2, pp. 84-90

2007

  1. Ampicillin-resistant non-β-lactamase-producing Haemophilus influenzae in Spain: Recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime

    Antimicrobial Agents and Chemotherapy, Vol. 51, Núm. 7, pp. 2564-2573

  2. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine coadministered with a diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months

    Pediatric Infectious Disease Journal, Vol. 26, Núm. 1, pp. 1-7

  3. Impact of amoxicillin, associated or not with clavulanic acid, on pharyngeal colonization and selection of Streptococcus pneumoniae resistance in children under 5 years of age

    European Journal of Pediatrics, Vol. 166, Núm. 5, pp. 467-471